Handbook of Hematologic Malignancies

David A. Sallman, MD, Associate Member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida Morsani College of Medicine, Tampa, FloridaAteefa Chaudhury, MD, Hematologist, New Mexico Cancer Center, Albuquerque, New MexicoHayder Saeed, MD, Associate member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FloridaLing Zhang, MD, Senior Member, Professor, Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

• ContributorsPrefaceAbbreviationsPART I. INTRODUCTION AND OVERVIEW1. Normal Hematopoiesis and Diagnosis Algorithms for Cytopenias and Cytoses2. ICC and WHO Classifications and Potential Future Harmonization3. Familial/Inherited Variants and Risks of Hematologic Malignancies4. Diagnostic Approaches to Hematologic Malignancies5. Minimal Residual Disease Assays6. Personalized Approach to Hematologic MalignanciesPART II. MYELOPROLIFERATIVE NEOPLASMS7. Polycythemia Vera8. Essential Thrombocythemia9. Primary Myelofibrosis10. Chronic Myelogenous Leukemia11. Chronic Neutrophilic Leukemia12. Systemic Mastocytosis13. Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion (MLN-TK)PART III. MYELODYSPLASTIC AND BONE MARROW FAILURE SYNDROMES14. CHIP, CCUS and Precursor States of Myeloid Neoplasms15. Myelodysplastic Syndromes16. Aplastic Anemia17. Paroxysmal Nocturnal HemoglobinuriaPART IV. MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS18. Myelodysplastic/Myeloproliferative Neoplasms19. Chronic Myelomonocytic LeukemiaPART V. ACUTE MYELOID LEUKEMIA AND RELATED SYNDROMES20. Acute Myeloid Leukemia21. Secondary AML and AML-MRC22. Acute Promyelocytic Leukemia23. Blastic Plasmacytoid Dendritic Cell NeoplasmPART VI. ACUTE LYMPHOID LEUKEMIA24. B-Lymphoblastic Leukemia/Lymphoma25. BCR-ABL1+ B-Lymphoblastic Leukemia26. T-Cell Acute Lymphoblastic Leukemia/LymphomaPART VII. ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE27. Acute Leukemia of Ambiguous LineagePART VIII. MATURE T- AND NK-CELL LEUKEMIA28. T-Cell Prolymphocytic Leukemia29. T-Cell Large Granular Lymphocytic Leukemia30. Aggressive Natural Killer Cell LeukemiaPART IX. PLASMA CELL DISORDERS31. Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and Plasmacytomas32. Multiple Myeloma33. Waldenström Macroglobulinemia34. Immunoglobulin Light Chain Amyloidosis ALPART X. HODGKIN LYMPHOMA35. Hodgkin LymphomaPART XI. NON-HODGKIN LYMPHOMA36. Diagnosis and Classification of Non-Hodgkin LymphomasPART XII. MATURE B-CELL LYMPHOMAVERY AGGRESIVE37. Burkitt LymphomaAGGRESSIVE38. Diffuse Large B-Cell Lymphoma39. Double-Hit Lymphoma40. Mantle Cell Lymphoma41. Primary Central Nervous System Lymphoma42. HIV-Related Lymphomas43. Follicular Lymphoma44. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma45. Hairy Cell Leukemia46. Marginal Zone LymphomaPART XIII. MATURE T- AND NK-CELL LYMPHOMA47. Peripheral T-Cell Lyphoma48. Adult T-Cell Leukemia/Lymphoma49. Anaplastic Large Cell Lymphoma50. Extranodal Natural Killer/T-Cell Lymphoma51. Mycosis Fungoides/Sézary Syndrome52. Hepatosplenic T-Cell LymphomaPART XIV. HISTIOCYTIC/DENDRITIC CELL NEOPLASMS53. Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Histiocytic Sarcoma54. Hemophagocytic LymphohistiocytosisPART XV. BONE MARROW TRANSPLANTATION55. Autologous Hematopoietic Cell Transplantation56. Allogeneic Hematopoietic Cell TransplantationPART XVI. NEW CELLULAR IMMUNOTHERAPY57. CAR-T Overview and Novel Cellular Therapeutic Options58. CD19 CAR T-Cell Therapy59. BCMA CAR T-Cell Therapy60. Cytokine Release Syndrome and Other Toxicities Associated With Cellular TherapiesPART XVII. EMERGENCIES IN HEMATOLOGY61. Cancer-Associated Thrombosis in Hematologic Malignancies62. Tumor Lysis Syndrome63. Thrombotic Microangiopathy64. Therapeutic Apheresis IndicationsAppendix: Pathology SupplementIndex